載入中
NASDAQHealthcareBiotechnology
最新資料
US$2.73
−US$0.05 · -1.80%
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
前收盤價
US$2.73
−US$0.05 · -1.80%
盤前
US$2.95
+US$0.22 · +8.06%
10月13日 上午7:26 ET
盤中時間採用ET。市場資料可能有所延遲。
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
日內區間
目前US$2.73
52週區間
目前US$2.73
盤中時間採用ET。市場資料可能有所延遲。
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
日內區間
目前US$2.73
52週區間
目前US$2.73
| 項目（USD） | 2025會計年度 |
|---|---|
| 營收 | 4萬 USD |
| 毛利 | 4萬 USD |
| 研究與開發 | 363.83萬 USD |
| 銷售、一般及管理費用 | 4285.44萬 USD |
| 營業費用 | 5820.92萬 USD |
| 利息收入 | 32.76萬 USD |
| 利息支出 | 250.46萬 USD |
| 折舊和攤銷 | 3.65萬 USD |
| 營業利益 | −5816.92萬 USD |
| 淨利 | −6214.62萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$16.00
上漲空間 486.08%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI153.44萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF92.96萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC9.32萬0.01%13.17億 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM2萬0.02%1.16億 USD0.73%US$15.8484-0.58%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
